JP2006045240A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006045240A5 JP2006045240A5 JP2005253346A JP2005253346A JP2006045240A5 JP 2006045240 A5 JP2006045240 A5 JP 2006045240A5 JP 2005253346 A JP2005253346 A JP 2005253346A JP 2005253346 A JP2005253346 A JP 2005253346A JP 2006045240 A5 JP2006045240 A5 JP 2006045240A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- carbamoyl
- methylthio
- carbamoylmethoxy
- dioxo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 23
- -1 carboxyl hydroxy group Chemical group 0.000 claims 18
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 125000006239 protecting group Chemical group 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 claims 3
- 239000000651 prodrug Substances 0.000 claims 3
- 229940002612 prodrug Drugs 0.000 claims 3
- 208000032928 Dyslipidaemia Diseases 0.000 claims 2
- 229940125922 IBAT inhibitor Drugs 0.000 claims 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- CWHZHSAJEOKUOJ-SFHVURJKSA-N (2s)-2-ethoxy-3-[4-[2-[[2-fluoro-4-(trifluoromethyl)phenyl]methylamino]-2-oxoethoxy]phenyl]propanoic acid Chemical compound C1=CC(C[C@H](OCC)C(O)=O)=CC=C1OCC(=O)NCC1=CC=C(C(F)(F)F)C=C1F CWHZHSAJEOKUOJ-SFHVURJKSA-N 0.000 claims 1
- OZIFULIQIAYMBA-SFHVURJKSA-N (2s)-2-ethoxy-3-[4-[2-oxo-2-[[4-(trifluoromethoxy)phenyl]methylamino]ethoxy]phenyl]propanoic acid Chemical compound C1=CC(C[C@H](OCC)C(O)=O)=CC=C1OCC(=O)NCC1=CC=C(OC(F)(F)F)C=C1 OZIFULIQIAYMBA-SFHVURJKSA-N 0.000 claims 1
- QVGLWHSPHJQMLW-SFHVURJKSA-N (2s)-3-[4-[2-[(4-chlorophenyl)methylamino]-2-oxoethoxy]phenyl]-2-ethoxypropanoic acid Chemical compound C1=CC(C[C@H](OCC)C(O)=O)=CC=C1OCC(=O)NCC1=CC=C(Cl)C=C1 QVGLWHSPHJQMLW-SFHVURJKSA-N 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims 1
- 239000003529 anticholesteremic agent Substances 0.000 claims 1
- 229940127226 anticholesterol agent Drugs 0.000 claims 1
- 229960005370 atorvastatin Drugs 0.000 claims 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 1
- 239000012351 deprotecting agent Substances 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 239000012442 inert solvent Substances 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 235000019260 propionic acid Nutrition 0.000 claims 1
- 229960000672 rosuvastatin Drugs 0.000 claims 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- BXVYJQULAWJPSR-UHFFFAOYSA-N thiadiazepine Chemical compound S1C=CC=CN=N1 BXVYJQULAWJPSR-UHFFFAOYSA-N 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 0 CCc1cc(*=*)c(*NC(COc2ccc(CC(C(O*)=O)OCC)cc2)=*)cc1 Chemical compound CCc1cc(*=*)c(*NC(COc2ccc(CC(C(O*)=O)OCC)cc2)=*)cc1 0.000 description 1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0229931.1A GB0229931D0 (en) | 2002-12-21 | 2002-12-21 | Therapeutic agents |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004561668A Division JP3786945B2 (ja) | 2002-12-21 | 2003-12-19 | 治療薬剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006045240A JP2006045240A (ja) | 2006-02-16 |
| JP2006045240A5 true JP2006045240A5 (enExample) | 2006-08-24 |
Family
ID=9950253
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004561668A Expired - Fee Related JP3786945B2 (ja) | 2002-12-21 | 2003-12-19 | 治療薬剤 |
| JP2005253346A Pending JP2006045240A (ja) | 2002-12-21 | 2005-09-01 | 治療薬剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004561668A Expired - Fee Related JP3786945B2 (ja) | 2002-12-21 | 2003-12-19 | 治療薬剤 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US7462644B2 (enExample) |
| EP (1) | EP1572626A1 (enExample) |
| JP (2) | JP3786945B2 (enExample) |
| KR (1) | KR20050089065A (enExample) |
| CN (1) | CN1308291C (enExample) |
| AR (1) | AR042632A1 (enExample) |
| AU (1) | AU2003290309B2 (enExample) |
| BR (1) | BR0317458A (enExample) |
| CA (1) | CA2508851A1 (enExample) |
| CL (1) | CL2003002683A1 (enExample) |
| CO (1) | CO5580820A2 (enExample) |
| GB (1) | GB0229931D0 (enExample) |
| IS (1) | IS7946A (enExample) |
| MX (1) | MXPA05006812A (enExample) |
| NO (1) | NO20052914L (enExample) |
| PL (1) | PL377144A1 (enExample) |
| RU (1) | RU2005117792A (enExample) |
| TW (1) | TW200508180A (enExample) |
| UA (1) | UA80729C2 (enExample) |
| WO (1) | WO2004056748A1 (enExample) |
| ZA (1) | ZA200504730B (enExample) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0229931D0 (en) | 2002-12-21 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
| SE0104333D0 (sv) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
| GB0314079D0 (en) | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| SE0104334D0 (sv) * | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
| CN100503599C (zh) | 2002-03-13 | 2009-06-24 | 詹森药业有限公司 | 作为组蛋白脱乙酰酶的新颖抑制剂的羰基氨基衍生物 |
| KR20040094672A (ko) | 2002-03-13 | 2004-11-10 | 얀센 파마슈티카 엔.브이. | 히스톤 디아세틸라제의 신규한 저해제로서의설포닐아미노-유도체 |
| WO2003076400A1 (en) | 2002-03-13 | 2003-09-18 | Janssen Pharmaceutica N.V. | New inhibitors of histone deacetylase |
| HRP20040804A2 (en) | 2002-03-13 | 2005-02-28 | Janssen Pharmaceutica N.V. | Piperazinyl-, piperidinyl- and morpholinyl-derivatives as novel inhibitors of histone deacetylase |
| PL375074A1 (en) | 2002-06-20 | 2005-11-14 | Astrazeneca Ab | Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance |
| BRPI0406761A (pt) | 2003-01-14 | 2005-12-20 | Arena Pharm Inc | Derivados de arila e heteroarila 1,2,3-trissubstituìdos como moduladores do metabolismo e a profilaxia e tratamento de distúrbios relacionados a estes tais como diabetes e hiper-glicemia |
| AR045697A1 (es) | 2003-07-14 | 2005-11-09 | Arena Pharm Inc | Aril y heteroaril derivados fusionados como moduladores del metabolismo y la prevencion y tratamiento de trastornos relacionados con el mismo |
| US8193205B2 (en) | 2004-07-28 | 2012-06-05 | Janssen Pharmaceutica N.V. | Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase |
| EP1811991B1 (en) * | 2004-11-10 | 2018-11-07 | Genzyme Corporation | Treatment of type 2 diabetes using inhibitors of glycosphingolipid synthesis |
| MY148521A (en) | 2005-01-10 | 2013-04-30 | Arena Pharm Inc | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
| EP1885710B1 (en) | 2005-05-18 | 2015-08-19 | Janssen Pharmaceutica N.V. | Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase |
| JP2008542355A (ja) | 2005-05-31 | 2008-11-27 | ファイザー株式会社 | Ｖｒ１アンタゴニストとしての置換アリールオキシ−ｎ−ビシクロメチルアセトアミド化合物 |
| WO2007004957A1 (en) * | 2005-07-05 | 2007-01-11 | Astrazeneca Ab | Novel crystalline form |
| AR055073A1 (es) * | 2005-07-11 | 2007-08-01 | Astrazeneca Ab | Agentes terapeuticos |
| US8101616B2 (en) | 2006-01-19 | 2012-01-24 | Janssen Pharmaceutica N.V. | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
| PT1981874E (pt) | 2006-01-19 | 2009-09-02 | Janssen Pharmactuica N V | Derivados de aminofenil como novos inibidores de histonadesacetilase |
| CA2635015C (en) | 2006-01-19 | 2014-06-03 | Janssen Pharmaceutica N.V. | Substituted indolyl-alkyl-amino-derivatives as inhibitors of histone deacetylase |
| ES2396986T3 (es) | 2006-01-19 | 2013-03-01 | Janssen Pharmaceutica N.V. | Derivados de piridina y pirimidina como inhibidores de histona desacetilasa |
| EP1979328B1 (en) | 2006-01-19 | 2012-12-26 | Janssen Pharmaceutica N.V. | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
| ES2376121T3 (es) | 2006-01-19 | 2012-03-09 | Janssen Pharmaceutica, N.V. | Derivados de heterociclilalquilo como nuevos inhibidores de histona deacetilasa. |
| PT2032134E (pt) | 2006-05-09 | 2015-10-07 | Genzyme Corp | Métodos de tratamento da doença do fígado gorduroso |
| EP2594563B1 (en) | 2007-05-31 | 2018-07-18 | Genzyme Corporation | 2-acylaminopropanol-type glucosylceramide synthase inhibitors |
| SG10201707161PA (en) | 2007-10-05 | 2017-10-30 | Genzyme Corp | Method of treating polycystic kidney diseases with ceramide derivatives |
| US8389517B2 (en) | 2008-07-28 | 2013-03-05 | Genzyme Corporation | Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease |
| CA2738768C (en) | 2008-10-03 | 2017-10-31 | Genzyme Corporation | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors |
| US9339480B2 (en) * | 2008-11-26 | 2016-05-17 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of obesity and diabetes |
| US20110294767A1 (en) | 2010-05-26 | 2011-12-01 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
| SG188548A1 (en) | 2010-09-22 | 2013-04-30 | Arena Pharm Inc | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| EP3400944B1 (en) | 2010-11-04 | 2020-07-15 | Albireo AB | Ibat inhibitors for the treatment of liver diseases |
| JO3301B1 (ar) | 2013-04-26 | 2018-09-16 | Albireo Ab | تعديلات بلورية على إيلوبيكسيبات |
| JP6751020B2 (ja) | 2014-06-25 | 2020-09-02 | Ｅａファーマ株式会社 | 固形製剤及びその着色防止又は着色低減方法 |
| EP3012252A1 (en) | 2014-10-24 | 2016-04-27 | Ferring BV | Crystal modifications of elobixibat |
| AU2016205361C1 (en) | 2015-01-06 | 2021-04-08 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
| CA3002551A1 (en) | 2015-06-22 | 2016-12-29 | Arena Pharmaceuticals, Inc. | Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(com pound 1)for use in s1p1 receptor-associated disorders |
| US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
| US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| CA3053418A1 (en) | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
| CN111032019B (zh) | 2017-08-09 | 2022-07-05 | 阿尔比里奥公司 | 考来烯胺颗粒、口服考来烯胺制剂及其用途 |
| US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| TW202015699A (zh) | 2018-06-05 | 2020-05-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽汁酸調節劑之用途 |
| CA3102136A1 (en) | 2018-06-06 | 2019-12-12 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the s1p1 receptor |
| US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
| SG11202012170PA (en) | 2018-06-20 | 2021-01-28 | Albireo Ab | Pharmaceutical formulation of odevixibat |
| US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
| EP3921028B1 (en) | 2019-02-06 | 2022-11-09 | Albireo AB | Benzothiadiazepine compounds and their use as bile acid modulators |
| US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
| PE20230234A1 (es) | 2019-12-04 | 2023-02-07 | Albireo Ab | Compuestos de benzoti(di)azepina y su uso como moduladores del acido biliar |
| JP7696898B2 (ja) | 2019-12-04 | 2025-06-23 | アルビレオ・アクチボラグ | ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
| US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| CN114761018B (zh) | 2019-12-04 | 2025-12-02 | 阿尔比里奥公司 | 苯并硫杂二氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| EP4069361B1 (en) | 2019-12-04 | 2024-01-03 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
| JP7748451B2 (ja) | 2020-08-03 | 2025-10-02 | アルビレオ・アクチボラグ | ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
| EP4243831A1 (en) | 2020-11-12 | 2023-09-20 | Albireo AB | Odevixibat for treating progressive familial intrahepatic cholestasis (pfic) |
| CA3198216A1 (en) | 2020-12-04 | 2022-06-09 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| TW202313579A (zh) | 2021-06-03 | 2023-04-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE266121C (enExample) | ||||
| BE489216A (enExample) | 1948-06-05 | 1900-01-01 | ||
| US2928840A (en) * | 1958-11-26 | 1960-03-15 | Us Vitamin Pharm Corp | 3-(o-substituted phenyl) oxazolidinediones and process therefor |
| GB1081471A (en) | 1963-09-13 | 1967-08-31 | Stauffer Chemical Co | Glycol amide derivatives and use thereof in controlling weed growth |
| US3244398A (en) * | 1963-10-28 | 1966-04-05 | Scaramucci Domer | Composite seat ball valve |
| AT307640B (de) | 1970-06-18 | 1973-05-25 | Richter Gedeon Vegyeszet | Verfahren zur Herstellung von neuen 17-Aza-steroiden und deren Salzen |
| BE792364A (fr) | 1971-12-06 | 1973-06-06 | Basf Ag | Derives de substitution du sulfonylglycolanilide |
| DE2349256C2 (de) | 1973-10-01 | 1985-08-01 | Basf Ag, 6700 Ludwigshafen | 0-Alkylsulfonyl-glykolsäureanilide und diese enthaltende Herbizide |
| DE2828222A1 (de) | 1978-06-28 | 1980-01-10 | Bayer Ag | Gegenmittel zum schutz von kulturpflanzen vor schaedigungen durch herbizide |
| US4735959A (en) * | 1981-01-10 | 1988-04-05 | Dr. Karl Thomae Gmbh | Carboxylic acid amides and pharmaceutical compositions containing them |
| US5216167A (en) * | 1983-12-30 | 1993-06-01 | Dr. Karl Thomae Gmbh | Phenylacetic acid benzylamides |
| US5312924A (en) * | 1983-12-30 | 1994-05-17 | Dr. Karl Thomae Gmbh | Phenylacetic acid benzylamides |
| US5210208A (en) * | 1990-09-24 | 1993-05-11 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Disubstituted aryl compounds exhibiting selective leukotriene b4 antagonist activity |
| US5958792A (en) | 1995-06-07 | 1999-09-28 | Chiron Corporation | Combinatorial libraries of substrate-bound cyclic organic compounds |
| EP1019364B1 (en) | 1997-08-28 | 2004-06-09 | Biovitrum Ab | Inhibitors of protein tyrosine phosphatase |
| US6410585B1 (en) * | 1997-08-28 | 2002-06-25 | Scott D. Larsen | Inhibitors of protein tyrosine phosphatase |
| HUP0003881A3 (en) * | 1997-10-02 | 2001-04-28 | Sankyo Co | Amidocarboxylic acid derivatives |
| CA2309792A1 (en) | 1997-11-12 | 1999-05-20 | William C. Shakespeare | Novel signal transduction inhibitors, compositions containing them |
| SE9801992D0 (sv) * | 1998-06-04 | 1998-06-04 | Astra Ab | New 3-aryl-2-hydroxypropionic acid derivative I |
| RU2219172C2 (ru) | 1999-04-06 | 2003-12-20 | Санкио Компани, Лимитед | α-ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ КАРБОНОВЫХ КИСЛОТ |
| JP2000351777A (ja) * | 1999-04-08 | 2000-12-19 | Sankyo Co Ltd | 置換縮合イミダゾール誘導体 |
| WO2000061582A1 (en) | 1999-04-08 | 2000-10-19 | Sankyo Company, Limited | Substituted fused imidazole derivatives |
| WO2000061584A1 (en) | 1999-04-14 | 2000-10-19 | The University Of British Columbia | IMPROVED β,β,-DIHYDROXY MESO-SUBSTITUTED CHLORINS, ISOBACTERIOCHLORINS, AND BACTERIOCHLORINS |
| WO2000063196A1 (en) | 1999-04-20 | 2000-10-26 | Novo Nordisk A/S | New compounds, their preparation and use |
| PT1177187E (pt) | 1999-04-28 | 2007-09-03 | Sanofi Aventis Deutschland | Derivados ácidos de di-arilo como ligados do receptor ppar. |
| JP4618845B2 (ja) | 1999-06-09 | 2011-01-26 | 杏林製薬株式会社 | ヒトペルオキシゾーム増殖薬活性化受容体（ＰＰＡＲ）αアゴニストとしての置換フェニルプロピオン酸誘導体 |
| TWI262185B (en) * | 1999-10-01 | 2006-09-21 | Eisai Co Ltd | Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives |
| JP2001261612A (ja) | 2000-03-22 | 2001-09-26 | Mitsui Chemicals Inc | カテコールプロピオン酸誘導体およびそれを有効成分として含有する核内レセプター作動薬 |
| JPWO2002044127A1 (ja) | 2000-11-29 | 2004-04-02 | 杏林製薬株式会社 | 置換カルボン酸誘導体 |
| AU2002222550A1 (en) | 2000-11-29 | 2002-06-11 | Kyorin Pharmaceutical Co. Ltd. | Substituted carboxylic acid derivatives |
| EP1360172A1 (en) | 2001-02-15 | 2003-11-12 | Pfizer Products Inc. | Ppar agonists |
| WO2002083616A1 (en) | 2001-04-10 | 2002-10-24 | Sankyo Company, Limited | α-SUBSTITUTED φ-ARYLFATTY ACID DERIVATIVE |
| GB0314079D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| SE0104334D0 (sv) * | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
| GB0229931D0 (en) | 2002-12-21 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
| BR0311834A (pt) * | 2002-06-19 | 2005-04-12 | Lilly Co Eli | Composto, composição farmacêutica, métodos para mudular um receptor ativado por proliferador de peroxisoma, para tratar e prevenir diabetes mellitus em um mamìfero e para tratar sìndrome x em um mamìfero, e, uso de um composto ou seu sal farmaceuticamente aceitável |
| GB0314129D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| GB0314134D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| GB0314136D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
-
2002
- 2002-12-21 GB GBGB0229931.1A patent/GB0229931D0/en not_active Ceased
-
2003
- 2003-12-10 TW TW092134839A patent/TW200508180A/zh unknown
- 2003-12-18 CL CL200302683A patent/CL2003002683A1/es unknown
- 2003-12-19 KR KR1020057011714A patent/KR20050089065A/ko not_active Withdrawn
- 2003-12-19 EP EP03782668A patent/EP1572626A1/en not_active Withdrawn
- 2003-12-19 WO PCT/GB2003/005602 patent/WO2004056748A1/en not_active Ceased
- 2003-12-19 UA UAA200505596A patent/UA80729C2/uk unknown
- 2003-12-19 US US10/499,893 patent/US7462644B2/en not_active Expired - Fee Related
- 2003-12-19 BR BR0317458-1A patent/BR0317458A/pt not_active IP Right Cessation
- 2003-12-19 PL PL377144A patent/PL377144A1/pl not_active Application Discontinuation
- 2003-12-19 CN CNB2003801098952A patent/CN1308291C/zh not_active Expired - Fee Related
- 2003-12-19 JP JP2004561668A patent/JP3786945B2/ja not_active Expired - Fee Related
- 2003-12-19 AR ARP030104752A patent/AR042632A1/es unknown
- 2003-12-19 CA CA002508851A patent/CA2508851A1/en not_active Abandoned
- 2003-12-19 MX MXPA05006812A patent/MXPA05006812A/es unknown
- 2003-12-19 AU AU2003290309A patent/AU2003290309B2/en not_active Ceased
- 2003-12-19 RU RU2005117792/04A patent/RU2005117792A/ru not_active Application Discontinuation
-
2005
- 2005-06-15 NO NO20052914A patent/NO20052914L/no not_active Application Discontinuation
- 2005-06-22 ZA ZA200504730A patent/ZA200504730B/en unknown
- 2005-07-19 CO CO05071340A patent/CO5580820A2/es not_active Application Discontinuation
- 2005-07-19 IS IS7946A patent/IS7946A/is unknown
- 2005-09-01 JP JP2005253346A patent/JP2006045240A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006045240A5 (enExample) | ||
| RU2005117792A (ru) | Терапевтические агенты | |
| RU2004116917A (ru) | Производные замещенной фенлпропионовой кислоты как агонисты активируемого пролифератором пероксисом альфа рецептора человека | |
| AU2004249409B2 (en) | Propionic acid derivatives useful in the treatment of lipid disorders | |
| RU2008129204A (ru) | Применение ингибитора ibat для лечения или профилактики запора | |
| CA2431461A1 (en) | 1,5 benzothiazepines and their use as antihyperlipidemics | |
| RU2005100836A (ru) | Производные пептидов, содержащие тиазепиновую группу, для лечения гиперлипемических состояний | |
| US7521461B2 (en) | Benzoic acid derivatives as modulators of PPAR alpha and gamma | |
| JP3822900B1 (ja) | カルボン酸誘導体の製剤上有用な塩 | |
| JP2005511785A5 (enExample) | ||
| RU2004117776A (ru) | Производные 3-фенил-2-арилалкилтиопропионовой кислоты в качестве селективных антагонистов ppar-альфа | |
| JP3836498B1 (ja) | 医薬として有用なカルボン酸誘導体の塩類 | |
| EP1638930A1 (en) | Amine salts of (-)-2- ¬2-(4-hydroxyphenyl)ethyl|-thio -3-¬4-(2- 4-¬(methylsulfonyl)oxy|phenoxy ethyl)phenyl|propanoic acid and their use in medicine. | |
| KR20050014013A (ko) | 인슐린 내성의 치료를 위한 오르토-치환 벤조산 유도체 | |
| RU2288912C2 (ru) | Ортозамещенные производные бензойной кислоты, способ и промежуточные соединения для их получения, фармацевтическая композиция на их основе и применение | |
| KR20060026427A (ko) | (-)-2-([2-(4-히드록시페닐)에틸]티오)-3-[4-(2-(4-[(메틸설포닐)옥시]페녹시)에틸)페닐]-프로판산 칼륨염 또는나트륨염 및 이들의 약제로서의 용도 | |
| WO2007008156A1 (en) | A pharmaceutical composition comprising a substituted phenylpropionic acid as a free acid and as tert-butyl amine salt thereof |